Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates, as ...

Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth ...

Tesla reported fourth-quarter revenue and adjusted profit below analysts' estimates. Shares initially fell and then rose ...

Reports Q4 revenue $753M, consensus $740.91M. “Our Q4 results were toward the high end of our guidance range, driven by demand in our Semi Test ...

Teradyne forecast first-quarter revenue below Wall Street estimates on Wednesday, indicating softening demand for its semiconductor-testing equipment.

We assign Teva a Morningstar Uncertainty Rating of High, which largely reflects our quantitative analysis of the firm, based on the return ranges used by our star rating system, as well as our ...

Tempus AI claims to have a one-stop-shop, with a flywheel platform that becomes better with each new client. See why I rate ...

Keros Therapeutics, Inc. (KROS) shares soared 5.1% in the last trading session to close at $11.41. The move was backed by solid volume with far more shares changing hands than in a normal session.

Endometriosis treatment market Insights. BURLINGAME, CA, UNITED STATES, January 16, 2025 /EINPresswire / -- This report on the Endometriosis Treatment Mark ...

L-R (Sanjay Patel, Gabriele Ricci, Tilak Banerjee of Takeda) Japanese pharmaceutical company Takeda ... Budget with ET Budget 2025: A CFO’s playbook for operational excellence and long-term growth ...

The company showed impressive growth and efficiency improvements across key financial metrics, demonstrating its commitment to both business expansion and operational optimization. The company ...